AbbVie (ABBV) Raises Quarterly Dividend 11.8% to $0.57; 4.2% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
UBS Reiterates Buy on AbbVie (ABBV) Following Conference Call
November 2, 2015 9:58 AM ESTUBS reiterated a Buy rating and $78.00 price target on Abbvie (NYSE: ABBV) following the company's conference call. Management assumes no biosimiliars before 2022, and low mid-single digit annual price increases. On Humira biosimilar, management believes US biosimilars will likely infringe its dosing patents as they have to demonstrate efficacy at equal dosing.
Analyst... More
AbbVie (ABBV) Reports Strong 3Q and Long term outlook; Cowen Reiterates Outperform
October 30, 2015 1:23 PM EDTCowen reiterated an Outperform rating and $77.00 price target on Abbvie (NYSE: ABBV) following the company's 3Q earnings results. Q3 EPS of $1.13 was $0.06 above consensus. Full year guidance has been raised to $4.26-4.28 (prior $4.10-4.30). Q3 sales of $5,944MM (+18%) were $54MM above... More
AbbVie (ABBV) Tops Q3 EPS by 7c; Guides FY15 EPS Above Views
October 30, 2015 6:56 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $1.13, $0.07 better than the analyst estimate of $1.06. Revenue for the quarter came in at $4.94 billion versus the consensus estimate of $5.9 billion.
Third-quarter sales growth was driven by the continued strength of HUMIRA and other promoted... MoreAbbVie (ABBV) Issues Long-Term Outlook; Boosts Qtr. Dividend
October 30, 2015 6:55 AM EDTAbbVie (NYSE: ABBV) outlined the company's long-term strategic and financial objectives, including expectations for growth and other financial metrics over its long-range plan, through 2020.
"AbbVie is well-positioned to deliver strong top- and bottom-line performance through 2020 and beyond," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We have built a strong foundation, establishing growth platforms in some of the largest and most attractive market segments. And, we have a robust and compelling pipeline which will contribute significantly to our performance over our long-range-plan."
Based on continued strong performance from its existing... More
